Kenneth Carter

Dr. Carter is a key advisor to NeuImmune and will serve on its Board of Directors. He is a dynamic biotechnology industry executive and scientific leader with deep experience in early-stage company development.

Since 2010 he has been involved in starting several biotechnology companies as a co-founder, advisor, CEO, and/or member of the Board of Directors. Among other roles, Dr. Carter is currently chairman of Seneca, Inc (NASDAQ: SNCA) in Germantown, MD, and a senior advisor to Innoforce, Inc., in Hangzhou, China. Earlier in his career, he was a co-founder and CEO of Avalon Pharmaceuticals. Under his leadership, Avalon developed a pipeline of cancer drug candidates based on a novel high-throughput genomic screening technology and completed an IPO and listing on the NASDAQ Stock Market. Prior to Avalon, Dr. Carter was head of gene mapping at Human Genome Sciences, Inc. (now GlaxoSmithKline) where he was involved in the discovery of dozens of novel human proteins with therapeutic or diagnostic potential, particularly for the treatment of cancer. He is also engaged in a range of educational and teaching activities and holds an adjunct faculty position at Johns Hopkins University, where he teaches a course entitled “Creating a Biotechnology Enterprise.”